cost-analysis of treatment of pediatrics acute lymphoblastic leukemia based on all-bfm protocol

Cost-analysis of Treatment of Pediatrics Acute Lymphoblastic Leukemia based on ALL-BFM Protocol

Background Among all pediatric cancers acute lymphoblastic leukemia (ALL) is highly prevalent, butthe overall cost of ALL management is not well-known, there is a need to assess the Berlin-Frankfurt-Munster (BFM) protocol commonly used in ALL management in Iran. So, the aim of this study was to estimate direct and indirect costs of ALL treatment among children based on the ALL-BFM protocol from...

Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991).

In The Netherlands from July 1988 to October 1991, children (0 to 16 years of age) with de novo acute lymphoblastic leukemia (ALL) were treated according to protocol ALL-7 of the Dutch Childhood Leukemia Study Group (DCLSG). In this protocol, chemotherapy and treatment stratification were identical to the ALL-BFM-86 protocol (Reiter et al, Blood 84:3122, 1994), but cranial irradiation was restr...

DETERMINATION OF A SHARED EPITOPE ON CELLS FROM ACUTE MYELOGENIC LEUKEMIA (AML) AND T-ACUTE LYMPHOBLASTIC LEUKEMIA ( T-ALL)

Two IgM monoclonal antibodies (MAb) with strong reactivity for granulocytes and to a lesser extent for lurkat cell lines were established by immunizing BALBI c mice with a histiocytic cell line (UY37). These two MAbs (designated as 6C9 and 4C4) reacted with blast cells of T-acute lymphoblastic leukemia (T-ALL) and acute myelogenous leukemia (AML) patients as well as leukemic cells from pat...

Acute Lymphoblastic Leukemia (ALL)

Immunologic subclassification of acute lymphoblastic leukemia in childhood and prognosis (modified BFM protocol).

Acute lymphoblastic leukemias (ALLs) in childhood are clonal proliferations of lymphoid cells. It is now possible precisely to define stages of human lymphocyte differentiation using more traditional cell markers such as surface membrane immunoglobulin (SIg), sheep erythrocyte receptor (E), and cytochemical stains or highly specific monoclonal antibodies. The application of these immunologic me...

Clinical experiences with a modified BFM protocol in childhood acute lymphoblastic leukemia.

The most important problem in current therapy of childhood acute lymphoblastic leukemia (ALL) is a failure in over one-half of patients. We were unable to increase the failure-free survival of children with high risk ALL by a ten-drug regimen (modified LSA 2 L 2) above 30% at 6 years [1].